Deep Genomics (company)

Deep Genomics (company)

A genetic medicine company that build data platforms using synthetic biology, artificial intelligence and genetic medicine creating medical therapies.

Deep Genomics is a medical company focusing on using developing genetic based therapies. It builds artificial intelligence-driven platforms that guide the creation of new medical therapies by blending synthetic biology, artificial intelligence and genetic medicine.

Brendan Frey, Andrew Delong, Hannes Bretschneider and Hui Yuan Xiong founded Deep Genomics in 2015 in Toronto, Ontario, Canada. It has a growing team of geneticists, molecular biologists and chemists from University of Cambridge, Massachusetts Institute of Technology (MIT), Stanford University, University of Toronto, University of California, San Diego, University of Washington and University of Waterloo. It is funded by primarily by Bay Area investors and aims to develop new ways of detecting and treating disease using biologically accurate artificial intelligence technology.

Deep Genomics uses neural networks to analyze genomic data, allowing scientists to identify the genes that cause diseases and develop drugs that deal with them. It has also specialized in finding elusive and less direct disease triggers in a person’s genome. Deep learning can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer

Project Saturn

Project Saturn is the name of Deep Genomics artificially intelligent drug prediction and design platform. The project is analyzing over 69 billion oligonucleotides against 1 million gene targets and narrowing down their results to produce 1000 potential new compounds that will work to have the predicted biological affect. The platform is able to continuously improve its predictions in a closed loop based on its failures and successes in reference to human cells. The system is designed to predict what affect an antisense oligonucleotide compound (AGO) on human cells, taking into account individual genotype and multiple biological mechanisms.

Funding
Seed

On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital.

Series A

After completing its series A funding round on September 25th, 2017, Deep Genomics raised $13,000,000 in funding from Khosla Ventures and True Ventures.

Partnerships
Wave Life Sciences

Deep Genomics announced that it will begin working with Wave Life Sciences on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease.

Patents

Patent description
Inventor
Status
Date
App/pub number

Brendan John Frey, Andrew Thomas Delong, Hui Yuan Xiong

Application

2017-11-09

WO2017190211A1

Hui Yuan Xiong, Andrew Delong, Brendan Frey

Application

2017-01-26

US20170024642A1

Brendan Frey, Michael K.K. Leung, Andrew Thomas Delong, Hui Yuan Xiong, Babak Alipanahi, Leo J. Lee, Hannes Bretschneider

Application

2016-12-15

CA2894317A1

Timeline

April 10, 2018
Wave Life Sciences Partnership

Deep Genomics announced that it will begin working with Wave Life Sciences on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease.

September 25, 2017
Series A Funding Round

After completing its series A funding round on September 25th, 2017, Deep Genomics raised $13,000,000 in funding from Khosla Ventures and True Ventures.

November 8, 2015
Seed Funding Round

On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Deep Genomics funding round, September 2017
13,000,000
September 2017
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Arthur A. Levin

Benjamin Neale

Brendan Frey

Stephen Scherer

Steven F. Dowdy

Vern Norviel

Vinod Khosla

Yann LeCun

Further reading

Title
Author
Link
Type
Date

A sanctuary for startups: How an aging church became home to some of U of T's newest ventures

University of Toronto​

AI startup Deep Genomics lands financing as it aims to ‘flip medicine on its back’

Sean Silcoff

Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. - PubMed - NCBI

Kemaladewi Du, Maino E, Hyatt E, Hou H, Ding M, Place KM, Zhu X, Bassi P, Baghestani Z, Deshwar AG, Merico D, Xiong HY, Frey BJ, Wilson MD, Ivakine EA, Cohn RD

Academic paper

COSSMO: Predicting Competitive Alternative Splice Site Selection using Deep Learning

Hannes Bretschneider, Shreshth Gandhi, Khalid Zuberi, Amit Deshwar, Brendan Frey

Academic paper

Deep Genomics - MaRS Innovation

MaRS Innovation​

Deep learning of the tissue-regulated splicing code

Micheal Leung, Hui Yuan Xiong, Leo Lee, Brendan Frey

Academic paper

Genome-wide characteristics of de novo mutations in autism

Yang, L., Visel, A., Gozes, I., Francioli, L. C., Adzhubei, I. A., Sander, C., Bailey, A., Peter Szatmari, Anagnostou, E., Daniele Merico, Ronemus, M., Schotta, G., Lia D’Abate, Laird, P. W., De Rubeis, S., Yingrui Li, Henikoff, S., Carter, M. T., Wang, K., D’Gama, A. M., Bhooma Thiruvahindrapuram, Gordon, L., Yuhui Sun, Xiaomin Liu, Dong, S.

Academic paper

Inference Of The Human Polyadenylation Code

Michael Leung, Andrew Delong, Brendan Frey

Academic paper

IT pros are gearing up for AI to transform health care

Sam Charrington

Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets - IEEE Journals & Magazine

Michael Leung, Andrew Delong, Babak Alipanahi, Brendan Frey

Academic paper

Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets - IEEE Journals & Magazine

Michael Leung, Andrew Delong, Babak Alipanahi, Brendan Frey

Academic paper

Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning

Babak Alipanahi, Andrew Delong, Mathew Weirauch, Brendan Frey

Academic paper

The human splicing code reveals new insights into the genetic determinants of disease

Hui Xiong, Babak Alipanahi, Leo Lee, Hannes Bretscheider, Daniele Merico, Ryan Yuen, Yimin Hua, Serge Gueroussov, Hamed Najafabadi, Timothy Hughes, Quaid Morris, Yoseph Barash, Adrian Krainer, Nebojsa Jojic, Stephan Scherer, Benjamin Blencowe, Brendan Frey

Academic paper

This AI-powered genomics company is turning its attention to drug development

Will Knight

Wave Life Sciences and Deep Genomics Join Up to Splice

Ryan Black

Documentaries, videos and podcasts

Title
Date
Link

Brendan Frey - Genome Reprogramming

December 9, 2017

Brendan Frey — Deep Genomics: Changing the Course of Genomic Medicine

July 1, 2017

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Colin McClelland
November 24, 2020
financialpost
Canada's biotech health-care industry is booming amid the pandemic but industry faces challenges
Colin McClelland
December 11, 2020
financialpost
AbCellera stock price shoots up 185% in its debut on the Nasdaq stock exchange
Mark Terry
November 17, 2020
BioSpace
There are many examples of how biopharma is leveraging AI and forging partnerships with companies focused on AI for drug development and clinical trials. There have been a few recent AI-based partnerships as well.
BioSpace
November 17, 2020
BioSpace
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications
Amirah Al Idrus
November 17, 2020
FierceBiotech
Deep Genomics is wasting no time. Two weeks after hiring a new chief business officer to ramp up its partnering game, it's unveiling its first biopharma tie-up: BioMarin. The duo will use the Toronto biotech's artificial-intelligence-based drug discovery platform to discover new drugs for rare diseases.
Isabelle Kirkwood
November 10, 2020
BetaKit
Three organizations have brought on new team members to add to their leadership. Here's a breakdown of who is joining, and what they bring to the table.
Alex Keown
November 6, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Amirah Al Idrus
November 5, 2020
FierceBiotech
It's been a busy year for Deep Genomics. Since scoring $40 million in January, the Toronto-based biotech has been identifying new drug targets across multiple disease areas, turning up many more prospects than it could pursue on its own. Enter Amanda Kay, Ph.D., its new chief business officer, who will develop and oversee the company's partnering strategy.
BioSpace
November 5, 2020
BioSpace
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Amanda Kay, Ph.D., to the newly created role of Chief Business Officer.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.